Beyond ERBB2 amplification: RNA and proteomic HER2 assessment for pan-tumor treatment stratification
HER2-directed therapies are expanding across solid tumors, but ERBB2 amplification incompletely captures HER2 expression and pan-tumor IHC lacks standardiz